November 2, 2015
Takeda Pharmaceutical revealed on October 30 that it has discontinued the development of its investigational anticancer agent TAK-264 and hypertension treatment TAK-272. TAK-264, which has been in PII development in the US and Europe for the treatment of gastric and...read more